Market Overview

Prima BioMed Announces Granting of Patent Number US 9,244,059 Eentitled Cytotoxic Anti-LAG-3 Monoclonal Antibody and its Use in the Treatment or Prevention of Organ Transplant Rejection and Autoimmune Disease'


Prima BioMed Ltd (NASDAQ: PBMD)
announces the granting of patent number US 9,244,059 entitled "Cytotoxic anti-LAG-3 monoclonal
antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune
disease" by the United States Patent and Trademark Office.
The patent relates to Prima's IMP731 antibody (originally developed by Immutep).The granted
claims provide protection for specific sequences of the antibody and its use in depleting LAG-3
+ T
cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity
Rights for the development of the IMP731 antibody were granted in December 2010 to GSK who
have commenced first-in-human clinical trials of a proprietary antibody (GSK2831781) derived
from IMP731.
About IMP731 and GSK2831781
IMP731 and GSK2831781 are designed to specifically deplete potentially pathogenic, recently
activated, LAG-3 expressing T cells which are enriched at the disease site i


Related Articles (PBMD)

View Comments and Join the Discussion!

Posted-In: News Press Releases

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at